The board of directors, investors, and Michael exchanged an intense debate over the proposed acquisition by Aegis Pharmaceuticals. The conference room was charged with differing opinions, as some board members pointed out the immediate financial gain from the sale, whileothers raised concerns about the long-term impact on thpany''sinnovations and independence.


    "Ithink weshouldn''tsell,"one board member, Thomas, said firmly."The potential for growth in our R&D is too great to give up now.We''reon the cusp of breakthroughs that could redefine entiresectors of the medical industry."


    On the other side of the argument, another board member, Linda, countered,"Butyou''renot looking at the financial security this deal offers. Two hundred billion is not just a drop in the bucket. It secures our financial future and provides capital for new ventures without the risk."


    A younger board member, Eric, chimed in."I''vebeen quiet, but I will share with you my opinion. Our independence has allowed us to innovate without being tied to the short-term goals of investors. If we sell,we''reanswering to someoneelse''sagenda."


    "Exactly, andlet''snot underestimate our future market value based on current trends and our development pipeline.We''reselling ourselves short if we take this offer now. The technologieswe''redeveloping could be worth triplethat ifthey hit the market aswe''reprojecting,"Antote said.


    The room nodded, absorbingAntote''sconviction.


    "There''sno way we can make a decision with half of us differing from the other half,"Michael said, noting the division in the room."We need a unified front, whatever our decision is."


    "Then we need more information,"suggested another board member, Sarah."We shouldconduct a thorough analysis ofthe market trends and potential future earnings against this immediate offer.Let''snot make a decision in haste."


    "That''sprudent,"agreed Antoneitte."Decisions such as thiscan''tbe rushed. Mr. Reyes, please tell Mrs. Skies that shewon''tbe making the decisionshe''dlike immediately.


    "Oh, I will give her the answerter. For now, I want to confirm that we are going to think of the proposndit''lltake a week or monthto fully assess the implications of this deal,"Michael responded firmly.


    Seeing that therewasn''tany objection, Michael continued.


    "Very well, I will be adjourning this meeting now. Thank you for your input, itis all appreciated,"Michael bowed before the board members left the conference room.Asthe screens went dark, Michael remained seated, staring at the now nk monitors.


    "Looks like we are not going to sell our medical enterprise,"Juliet said, handing him abottle of water.


    Michaeltookthe water bottle andopened it, takinga long drink before responding.


    "Their reactionis expectedandI already knew it woulde to this,"Michael exined."Though half of them want to sell, I still feel their reluctanceover it.


    They knew thosepanieswere going togrow bigandItoobelievedthat.And I find it baffling that the Aegis Corporation is willing to buy it foraridiculousamount ofmoney.200billion over a fledglingpany?It''stoo good to be true for me."


    Juliet nodded, understandingMichael''shesitation."It does raise questions about their motives. What exactly do they see in our operations thatthey''rewilling to pay such a premiumfor?"


    "That''sexactly it,"Michael agreed, rubbing his chin thoughtfully."Medipod is the greatest threat to their market. They make a lot of money from their oncology drugs.They couldbe seeingMedipod as a disruptor that couldpotentiallyundercut their market share significantly in the future."


    Juliet''seyes widened as the pieces fell into ce."So,they''renot just buying our innovation, theymight be trying to eliminatepetition."


    Michael shook his head."Well, in a way. With them buying ourpany,they''dhave ess to Medipod, and the fact that when the cure for canceris discovered, many people will shift to that treatment. So they are recingus,and their market with ours, controlling the release to maximize their profits before any major market shift urs.It''sa strategic y."


    "That''ssomewhat sinister, but it makes sense from a business standpoint,"Juliet acknowledged."They''renot just investing;they''realso safeguarding their current market dominance."


    Michael sighed, his gaze still fixed on the empty screens."Exactly, Juliet. Andthat''swhy we must tread carefully. If Aegis controls our innovations,who''sto say theywon''tdy or restrict the development to fit their agenda?"


    Juliet considered this, her expression growing serious."So,what''sour strategy moving forward?"


    "Ithink weshouldn''tsell. I started thatpanysoI have to see it through to the end and let the world witness what we have to offer,"Michael stated resolutely."We''llcontinue to push forward with our projects. I need you to call Mrs. Skies so we can inform her of our decision."


    "Iwill call her right away,"Juliet said, picking up her phone to dial Elena Skies. Asshe stepped aside to make the call.


    After a brief conversation, Juliet returned."I''veinformed Mrs. Skiesandshe''llbe here shortly. I will escort her to your office once she arrives."


    "Good, thank you, Juliet. Make sure we have everything ready for the discussion. I want this to be clear and to the point,"Michael instructed, straightening his papers and preparing for another round of intense discussions.


    Juliet nodded and left to prepare the meeting room.


    A short whileter, Juliet escorted Elena Skies intoMichael''soffice. Elena,posed yet evidently eager to discuss the deal, greeted Michael with a firm handshake.


    "Mr. Reyes, I hopeyou''vereconsidered our generous offer,"Elena started, wasting no time.


    Michael motioned for her to take a seat."Mrs. Skies, we appreciate the value Aegis sees in our work. However, my board of directors is not leaning towardthe idea ofselling thepany. I also realized that Ishouldn''tsell mypany."


    Elena''sexpression tightened slightly."You are really refusing our generous offer?"


    "It''sgenerous indeed, but I believe in mypany. That would be all, Mrs. Skies,"Michael replied firmly.


    "Imust say, Mr. Reyes, your decision is disappointing but not unexpected. You have built remarkable technologies, andit''sunderstandable that you want to see them reach their full potential independently."


    Michael nodded."Thank you for your understanding, Mrs. Skies. Aegis Pharmaceuticals is a formidable yer in the industry, and whilewe decline this offer, I hope thiswon''tpreclude future coborations where ourpanies can work together on different terms."


    Elena stood, smoothing her suit jacket."The door remains open, Mr. Reyes. Should circumstances change, feel free to reach out."With a polite nod, she added,"I wish you the best with your endeavors."


    ***


    March 3rd, 2027.


    Elena was on her way to Man International Airport. She looked out of the window with a mncholic expression on her face.Her reasonswhyshewasin the Philippinesdidn''tturn out asshe hadnned.The meeting with Michael Reyes had ended without the agreement she had hoped for.


    The refusal of his board to sell thepany—left her feeling both frustrated and uncertain about the next steps for Aegis Pharmaceuticals.


    As the cityscape sped by,Elena''sthoughts drifted to the implications of this setback.The acquisition ofReyes MedTech and Reyes Pharmaceuticals was crucial toAegis''sstrategy to dominate the global medical technology market. Without it, herownposition within Aegis might be at risk. Most ofAegis''sprofitse from oncology drugs, soit''sonly natural for her to control it.


    "Should I resort to that action again?"Elena muttered under his breath.


    Well, it failed. Andshedoesn''twant to do that again assheknowsthere''ssomeone high-level involved in it. For example, the militia that she hired tokidnap,Mr. Vinueva were all dead in a ce where they were holding the doctor. The doctor was her way of knowing about the Medipod.


    Elena''seyes narrowed as she recalled the details. Shecouldn''tafford the potential legal repercussions. She tried being diplomaticbutthat too failed. She must stop Reyes at all costs from expanding and taking over the market herpany had long dominated. The stakes were too highandher role at Aegis demanded decisive action, albeit through more legitimate means.


    As the airport terminalcame into view, Elena dialed her chief strategist on her phone.


    "We need a new n,"she began without preamble."Reyes has resisted our acquisition attempt, andit''sclearhe will notbe easily swayed."


    "He resisted?That''s200 billion dors, theyrefused the acquisition?"


    "Unfortunately. This is whyI''mcalling you to inform you that we need to do something. Ican''tlet a young man thwart my ns and potentially damage our market position."@@novelbin@@


    Her strategist, sounding equally determined, replied,"Understood.I''llbegin by analyzing potential vulnerabilities in ReyesMedTech''sbusiness model and current market strategies.Perhapsthere are opportunitieswe''veoverlookedthat could give us apetitive edge without direct acquisition."


    "Do that."